Baytril 2.5% Injectable Solution
1 ml injectable solution contains 25 mg of enrofloxacin
Dogs, cats, rabbits, rodents, reptiles, and ornamental birds
Infections of the alimentary, respiratory, and urogenital tracts (incl. prostatitis, adjunctive antibiotic therapy for pyometra), skin and wound infections, otitis caused by enrofloxacin susceptible strains of: Staphylococcus spp., Escherichia coli, Pasteurella spp., Klebsiella spp., Bordetella spp., Pseudomonas spp., and Proteus spp.
Infections of the alimentary, respiratory, and urogenital tracts (as adjunctive antibiotic therapy for pyometra), skin, and wound infections, caused by enrofloxacin susceptible strains of: Staphylococcus spp., Escherichia coli, Pasteurella spp., Klebsiella spp., Bordetella spp., Pseudomonas spp., and Proteus spp.
Infections of the alimentary and respiratory tracts caused by enrofloxacin susceptible strains of: Escherichia coli, Pasteurella multocida, and Staphylococcus spp. Infections of skin and wound infections caused by enrofloxacin susceptible strains of Staphylococcus aureus.
Rodents, Reptiles, and Ornamental Birds
Treatment of infections of the alimentary and respiratory tracts where clinical experience, and where possible, supported by susceptibility testing of the causal organism, indicates enrofloxacin as the substance of choice.
Do not use in the case of known hypersensitivity to fluoroquinolones or to any of the excipients.
Do not use in animals that are epileptic or suffer from seizures since enrofloxacin may cause CNS stimulation.
Do not use in young dogs during their growth, i.e. in small breeds of dogs less than eight months of age, in big breeds of dogs less than 12 months of age, and in giant breeds of dogs less than 18 months of age.
Do not use in cats less than eight weeks of age.
Interaction with Other Medicinal Products
Do not use enrofloxacin concomitantly with antimicrobial substances acting antagonistically to quinolones (e.g. macrolides, tetracyclines, or phenicols).
Do not use concurrently with theophylline as the elimination of theophylline may be delayed.
Care should be taken during the concomitant use of flunixin and enrofloxacin in dogs to avoid adverse drug reactions. The decrease in drug clearances as a result of co-administration of flunixin and enrofloxacin indicates that these substances interact during the elimination phase. Thus, in dogs, the co-administration of enrofloxacin and flunixin increased the AUC and the elimination half-life of flunixin and increased the elimination half-life and reduced the Cmax of enrofloxacin.
Dogs and Cats
5 mg/kg bw – corresponding to 1 ml/5 kg bw – once daily by subcutaneous injection for up to five days.
10 mg/kg bw, corresponding to 2 ml/5 kg bw, once daily by subcutaneous injection for five to ten days.
10 mg/kg bw, corresponding to 0.4 ml/kg bw, once daily by subcutaneous injection for five to ten days.
If necessary, depending on the severity of clinical signs, this dosage can be doubled.
5–10 mg/kg bw, corresponding to 0.2–0.4 ml/kg bw, once daily by intramuscular injection for five days.
An extension of the treatment interval to 48 hours may be necessary in individual cases. In complicated infections, higher dosages and longer treatment courses may be necessary. The presence of the renal portal system in reptiles means it is prudent to administer substances in the front half of the body wherever possible.
Reptiles are ectothermic, relying on external heat sources to maintain their body temperature at the optimum level for correct function of all body systems. Metabolism of substances and activity of the immune system are, thus, critically dependent on the body temperature. Therefore, the veterinarian must be aware of the correct temperature requirements of the respective reptile species and the hydration status of the individual patient. Furthermore, it has to be considered that large differences exist in the pharmacokinetic behavior of enrofloxacin among different species, which additionally will influence the decision about the correct dosage. Therefore, the recommendations made here can only be used as a starting point for individual dose setting.
20 mg/kg bw, corresponding to 0.8 ml/kg bw, once daily by intramuscular injection for five to ten days.
In case of complicated infections, higher doses may be necessary.
Baytril® Flavored Tablets*
Enrofloxacin (15, 50, 150, and 250 mg per tablet) and excipients including artificial beef flavor.
Dog (15 mg and 50 tablet: dog and cat)*
Treatment of bacterial infections of the alimentary, respiratory, and urogenital tracts, skin, secondary wound infections, and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
Whenever possible, antibiotics should be used based on suceptibility testing.
Not for use in dogs less than one year of age or in exceptionally large breeds of dog with a longer growth period under 18 months of age, as articular cartilage may be affected during the period of rapid growth.
Dose and Administration
5 mg/kg bw for oral use once daily (optional: as a divided dose twice daily) for three to ten consecutive days with or without food.
Treatment may be initiated with Baytril® 5% injection or Baytril® 2.5% injection and maintained with Baytril® Flavor Tablets.
Please check your local SPC. The type and number of registered formulations, sizes, and their label declaration might vary by country.
Baytril® Flavored Oral Suspension for Cats*
Enrofloxacin 25 mg/ml and excipients incl. vanilla flavor
For the treatment of single or mixed bacterial infections of the respiratory, alimentary, and urinary tract, skin, or wounds caused by the following enrofloxacin-sensitive gram-negative and gram-positive bacteria: E.coli, Pasteurella spp., Haemophilus spp. and staphylococci.
Whenever possible, antibiotics should be used based on susceptibility testing.
Precautions and Contraindications
Use with caution in animals with severe renal or hepatic impairment.
Retinotoxic effects including irreversible blindness can occur in cats when the recommended dose is exceeded.
Do not use in cats with:
Existing impairment of cartilage growth
A known history of seizures, since enrofloxacin may cause CNS stimulation
Known hypersensitivity to fluoroquinolones or any type of excipients
Dose and administration
5 mg/kg bw for oral use once daily (equivalent to 0.2 ml per kg bw once daily) generally for five to ten consecutive days. Do not exceed the recommended dose.
*The product name might vary by country. Please check your local SPC.